Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
licensing
Biotech
Relmada dumps depression asset after slew of phase 3 failures
The biotech has terminated the license agreement for esmethadone, months after canceling two phase 3 trials that were not expected to hit their goals.
Darren Incorvaia
Jul 11, 2025 12:12pm
Genmab axes anti-CD38 antibody after losing J&J support
Mar 10, 2025 2:13pm
AbbVie exercises $40M option for Capsida-partnered gene therapy
Jan 7, 2025 10:45am
Elevar offers $500M biobucks for Relay's rare cancer asset
Dec 3, 2024 3:04pm
Roche bets up to $1B to expand Dyno gene therapy delivery pact
Oct 24, 2024 10:40am
Bayer pharma BD chief says group overhaul not slowing deals
Aug 15, 2024 2:30pm
